Payment overview · 2025
General Payments
$538.95
5 reported records · 3 companies
Healthcare provider profile · identity verified
Christopher W Swift, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine|Critical Care Medicine · MERIDIAN, MS · NPI 1023320280
Verified facts
What the public records show
CMS Open Payments records show Christopher W Swift, D.O. received $538.95 in general payments during 2025 across 5 reported records.
AstraZeneca Pharmaceuticals LP accounted for 57.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $311.15 | 57.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $125.00 | 23.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $102.80 | 19.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $538.95 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $117.65 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $102.80 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $96.75 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $96.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 81 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
81 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 427 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 427 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 395 | 114 |
| Pantoprazole Sodium | Pantoprazole Sodium | 390 | 117 |
| Gabapentin | Gabapentin | 362 | 100 |
| Metformin Hcl | Metformin Hcl | 290 | 83 |
| Furosemide | Furosemide | 271 | 61 |
| Eliquis | Apixaban | 263 | 44 |
| Losartan Potassium | Losartan Potassium | 257 | 83 |
| Potassium Chloride | Potassium Chloride | 251 | 54 |
| Omeprazole | Omeprazole | 247 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 218 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 181 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 174 | 43 |
| Lisinopril | Lisinopril | 171 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 166 | 50 |
| Carvedilol | Carvedilol | 163 | 42 |
| Escitalopram Oxalate | Escitalopram Oxalate | 152 | 42 |
| Trazodone Hcl | Trazodone Hcl | 149 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 45 |
| Sertraline Hcl | Sertraline Hcl | 135 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 33 |
| Allopurinol | Allopurinol | 123 | 28 |
| Meloxicam | Meloxicam | 118 | 36 |
| Montelukast Sodium | Montelukast Sodium | 118 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 106 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 99 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 97 | 14 |
| Donepezil Hcl | Donepezil Hcl | 95 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 93 | 18 |
| Ozempic | Semaglutide | 92 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 85 | 13 |
| Famotidine | Famotidine | 85 | 24 |
| Tramadol Hcl | Tramadol Hcl | 85 | 21 |
| Memantine Hcl | Memantine Hcl | 84 | 12 |
| Simvastatin | Simvastatin | 83 | 17 |
| Farxiga | Dapagliflozin Propanediol | 81 | 24 |
| Glipizide | Glipizide | 80 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 25 |
| Metformin Hcl Er | Metformin Hcl | 78 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 21 |
| Buspirone Hcl | Buspirone Hcl | 64 | 19 |
| Methocarbamol | Methocarbamol | 62 | 25 |
| Prednisone | Prednisone | 61 | 38 |
| Ondansetron Hcl | Ondansetron Hcl | 60 | 27 |
| Alprazolam | Alprazolam | 58 | 12 |
| Valsartan | Valsartan | 56 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 54 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 13 |
| Mirtazapine | Mirtazapine | 49 | 16 |
| Ezetimibe | Ezetimibe | 48 | 16 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 46 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 46 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Glipizide Er | Glipizide | 42 | 15 |
| Azithromycin | Azithromycin | 41 | 25 |
| Baclofen | Baclofen | 41 | suppressed |
| Celecoxib | Celecoxib | 41 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 41 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 13 |
| Methenamine Hippurate | Methenamine Hippurate | 39 | suppressed |
| Lorazepam | Lorazepam | 38 | 13 |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Fluconazole | Fluconazole | 37 | 22 |
| Pregabalin | Pregabalin | 37 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | 17 |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Linzess | Linaclotide | 34 | 12 |
| Promethazine Hcl | Promethazine Hcl | 34 | 16 |
| Chlorthalidone | Chlorthalidone | 32 | 12 |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Ibuprofen | Ibuprofen | 31 | 14 |
| Synthroid | Levothyroxine Sodium | 31 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Estradiol | Estradiol | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | 18 |
| Latanoprost | Latanoprost | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 21 |
| Brimonidine Tartrate | Brimonidine Tartrate | 26 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | 12 |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Brilinta | Ticagrelor | 25 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 21 |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | 11 |
| Sulfasalazine | Sulfasalazine | 25 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Glucagon Emergency Kit | Glucagon | 20 | suppressed |
| Metolazone | Metolazone | 20 | suppressed |
| Novolog | Insulin Aspart | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 13 |
| Trulicity | Dulaglutide | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Novolin R | Insulin Regular, Human | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Insulin Lispro | Insulin Lispro | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Colchicine | Colchicine | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 14 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | 11 |
| Nitroglycerin | Nitroglycerin | 13 | 11 |
| Olanzapine | Olanzapine | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Dotti | Estradiol | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Zaleplon | Zaleplon | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $538.95 · 5 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, EVENITY, FARXIGA, Ozempic | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error